Marc Beer is the chairman, CEO, and the founding partner of Renovia Inc. He is a phenomenal manager with more than 25 years of expertise and operational experience. He has primarily focused on biotechnology, pharmaceutical devices, and diagnostic devices development industries. He has a proven track of success record and a dynamic leadership character. Marc has served in numerous pharmaceutical firms where he has held top positions. Prior to founding Renovia Inc., he was the CEO of ViaCell. This is a well-known pharmaceutical and biotechnology firm specializing in the development, collection and preservation of the blood stem cells of the umbilical cord. The firm grew and expanded dramatically during his tenure in the company. He is also the co-founder of the Good Start Genetics Compensation Committee where he served as the board chairman. Additionally, he is a member of the business advisory committee of Miami University.
Recently, Marc Beer started Renovia Inc. on a mission to help improve the treatment of pelvic floor disorders treatment, particularly on women. He got this idea from a 70-year-old gynecologist who has been treating pelvic floor disorders over the last 35 years and has dedicated the last decade on finding ways treating the disorders without surgery. According to research, over 250 million women across the world suffer from pelvic floor disorders. Leading the firm with in-depth knowledge, expertise, and vast experience, Marc’s efforts focus on developing innovative pharmaceutical products that can diagnose and treat pelvic floor disorders such as urinary incontinence, prolapse, pelvic pain, pelvic floor dysfunction, rectocele, and dyssynergia without involving surgical procedures. Marc Beer has held a series of fund drives to fund his company and the various projects underway. The latest fund drive generated an overwhelming total of $42 million. This was overwhelming support received by the Boston-based biotech company which is an indicator of the faith and the hope investors, and well-wishers have for a better future in the treatment of pelvic disorders with the company.
Despite being a startup, Renovia Inc. has already established itself as a leading pharmaceutical devices development company. In April 2018, the company announced its first FDA-approved product, Leva. This is a product that will enhance the diagnosis and effective treatment of various pelvic floor disorders. This is the beginning of a bright vision to better diagnosis and treatment of women suffering pelvic floor disorders. The company will, however, focus on developing advanced and proprietary technologies as well as a digital health platform. This will help improve storage and retrieval of patient health records as well as provide diverse treatment options. Additionally, it will help lower the healthcare costs by reducing the treatment time while increasing the efficiency of the various procedures involved. Overall, the company through these products will help women reclaim control of their pelvic floors. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues